INDPIndaptus Therapeutics, Inc.

Nasdaq indaptusrx.com


$ 1.46 $ -0.08 (-5.3 %)    

Friday, 06-Sep-2024 15:58:23 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 1.43
$ 1.42 x 100
-- x --
-- - --
$ 1.41 - $ 4.08
29,232
na
14.58M
$ 1.32
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-13-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 indaptus-therapeutics-q2-eps-047-beats-054-estimate

Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-reiterates-buy-on-indaptus-therapeutics-maintains-12-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $...

 indaptus-therapeutics-to-present-new-positive-data-on-decoy20-at-next-gen-immuno-oncology-conference

Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and...

 indaptus-therapeutics-announces-new-data-from-ongoing-phase-1-trial-of-decoy20-latest-data-from-first-and-second-cohorts-support-companys-pulse-prime-approach-demonstrating-rapid-clearance-broad-immune-activation-and-encouraging-safety-profile

Latest data from first and second cohorts support Company's 'pulse-prime' approach, demonstrating rapid clearance, ...

 indaptus-therapeutics-presents-new-cohort-data-confirming-original-pulse-prime-hypothesis-via-phase-1-clinical-trial-of-decoy20-at-the-asco-annual-meeting

Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and...

 indaptus-therapeutics-first-patient-received-multiple-doses-of-decoy20-the-companys-broad-based-pulse-prime-immuno-oncology-therapy-for-advanced-solid-tumors

First-in-human trial confirms "Pulse-Prime" hypothesis targeting stimulation of innate and adaptive immune systemsInves...

 indaptus-therapeutics-q1-eps-045-misses-044-estimate

Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate ...

 hc-wainwright--co-reiterates-buy-on-indaptus-therapeutics-maintains-12-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $...

 indaptus-therapeutics-previews-mechanism-of-action-data-to-be-presented-at-the-american-association-for-cancer-research-annual-meeting

Data demonstrates that Company's Decoy platform successfully induces or activates multiple immune celltypes involved in ant...

 indaptus-therapeutics-fy-eps-183-beats-195-estimate-cash-balance-of-134m-will-provide-runway-through-q3-of-2024

Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(1.83) per share which beat the analyst consensus estimate of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION